PTC Therapeutics EVP, CLO Mark Elliott Boulding disposes of common shares worth $257,864.88

PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

PTCT

0.00
  • PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding reported option exercises and stock sales on July 6, 2026.
  • Exercised options for 5,079 shares at USD 39.42 and USD 46.54 per share.
  • Sold 5,079 shares at weighted-average prices ranging from USD 83.1 to USD 86.38 per share.
  • Directly held 105,272 shares following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000020), on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.